MetaVia has started higher-dose testing for DA-1726 in obesity. Read what this means for tolerability, competition, and the next clinical milestone.
Tenvie Therapeutics begins Phase 1 dosing of TNV262. Find out why this CNS-penetrant NLRP3 inhibitor could reshape obesity and CVD treatment.
Caliway’s CBL-514 heads to ADA 2026 with tirzepatide combination data. Read what this could change in obesity treatment strategy.
Sciwind Biosciences partners with Pfizer China on ecnoglutide. Explore what this GLP-1 deal changes for obesity, diabetes, and China’s drug market.
EU approves 7.2 mg Wegovy for obesity. Explore what this means for efficacy, competition and reimbursement across Europe.
Can TPC-026 fill the gap after GLP-1s? Find out how TETRAPHARM’s novel compound could reshape long-term metabolic care.
Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.
Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.
Zealand Pharma A/S and OTR Therapeutics have entered a multi-program strategic collaboration and licensing agreement to develop novel oral small-molecule therapies for metabolic diseases. The deal includes an initial payment of USD 20 million to OTR Therapeutics, which could increase to USD 30 million under predefined conditions. Total consideration may reach approximately USD 2.5 billion, […]
Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.